352 related articles for article (PubMed ID: 31323433)
21. More than a messenger: Alternative splicing as a therapeutic target.
Black AJ; Gamarra JR; Giudice J
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194395. PubMed ID: 31271898
[TBL] [Abstract][Full Text] [Related]
22. Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes.
Kim EY; Barefield DY; Vo AH; Gacita AM; Schuster EJ; Wyatt EJ; Davis JL; Dong B; Sun C; Page P; Dellefave-Castillo L; Demonbreun A; Zhang HF; McNally EM
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30730308
[TBL] [Abstract][Full Text] [Related]
23. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
24. RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.
Zu T; Cleary JD; Liu Y; Bañez-Coronel M; Bubenik JL; Ayhan F; Ashizawa T; Xia G; Clark HB; Yachnis AT; Swanson MS; Ranum LPW
Neuron; 2017 Sep; 95(6):1292-1305.e5. PubMed ID: 28910618
[TBL] [Abstract][Full Text] [Related]
25. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges.
Sicot G; Gourdon G; Gomes-Pereira M
Hum Mol Genet; 2011 Oct; 20(R2):R116-23. PubMed ID: 21821673
[TBL] [Abstract][Full Text] [Related]
26. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
27. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
28. The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing.
Pascual M; Vicente M; Monferrer L; Artero R
Differentiation; 2006 Mar; 74(2-3):65-80. PubMed ID: 16533306
[TBL] [Abstract][Full Text] [Related]
29. Context matters: Regulation of splice donor usage.
Ptok J; Müller L; Theiss S; Schaal H
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194391. PubMed ID: 31202784
[TBL] [Abstract][Full Text] [Related]
30. How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene.
Singh NN; Singh RN
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194403. PubMed ID: 31323435
[TBL] [Abstract][Full Text] [Related]
31. Partners in crime: Proteins implicated in RNA repeat expansion diseases.
Baud A; Derbis M; Tutak K; Sobczak K
Wiley Interdiscip Rev RNA; 2022 Jul; 13(4):e1709. PubMed ID: 35229468
[TBL] [Abstract][Full Text] [Related]
32. Nuclear localization of MBNL1: splicing-mediated autoregulation and repression of repeat-derived aberrant proteins.
Kino Y; Washizu C; Kurosawa M; Oma Y; Hattori N; Ishiura S; Nukina N
Hum Mol Genet; 2015 Feb; 24(3):740-56. PubMed ID: 25274774
[TBL] [Abstract][Full Text] [Related]
33. Alternative splicing regulation by Muscleblind proteins: from development to disease.
Fernandez-Costa JM; Llamusi MB; Garcia-Lopez A; Artero R
Biol Rev Camb Philos Soc; 2011 Nov; 86(4):947-58. PubMed ID: 21489124
[TBL] [Abstract][Full Text] [Related]
34. Intronic RNA: Ad'junk' mediator of post-transcriptional gene regulation.
Neil CR; Fairbrother WG
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194439. PubMed ID: 31682938
[TBL] [Abstract][Full Text] [Related]
35. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis.
Galvão R; Mendes-Soares L; Câmara J; Jaco I; Carmo-Fonseca M
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):191-201. PubMed ID: 11719250
[TBL] [Abstract][Full Text] [Related]
36. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
37. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
38. Myotonic dystrophy: RNA-mediated muscle disease.
Wheeler TM; Thornton CA
Curr Opin Neurol; 2007 Oct; 20(5):572-6. PubMed ID: 17885447
[TBL] [Abstract][Full Text] [Related]
39. Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a
Chakraborty M; Sellier C; Ney M; Pascal V; Charlet-Berguerand N; Artero R; Llamusi B
Dis Model Mech; 2018 Apr; 11(4):. PubMed ID: 29592894
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of RNA Metabolism in Microsatellite Expansion Diseases.
Misra C; Lin F; Kalsotra A
Adv Neurobiol; 2018; 20():213-238. PubMed ID: 29916021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
